首页> 外文期刊>Hormone research in p?diatrics >Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening
【24h】

Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening

机译:从干血斑的先天性肾上腺皮质增生的同时确认和鉴别诊断:第二层LC-MS / MS分析在新生儿筛查跨界合作中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Newborn screening for congenital adrenal hyperplasia (CAH) is generally performed using 17-hydroxyprogesterone dissociation-enhanced, lanthanide fluorescence immunoassay (DELFIA (R)). The primary screening results must be confirmed due to high false-positive rates; however, the need to obtain a separate specimen can hamper early recognition, differential diagnosis and treatment. We aimed to develop a single liquid chromatography-tandem mass spectrometry (LC-MS/MS) method that allows both the confirmation and differential diagnosis of CAH using the same dried blood spot (DBS) as in primary screening. Methods: An LC-MS/MS assay for cortisol, 21-deoxycortisol, 11-deoxycortisol, 4-androstenedione and 17-hydroxyprogesterone was developed, validated and applied to a total of 163 DBS samples tested positive in primary newborn screening in a cross-border cooperation. Results: Excellent baseline resolution and reliable determination of all analytes were achieved in DBS samples following simple sample preparation without derivatization. Of a total of 163 DBS samples tested positive in primary screening, the 21-hydroxylase-deficient form of CAH was confirmed in 1 sample. Conclusions: The present LC-MS/MS assay was successfully applied as a second-tier test in a cross-border cooperation for newborn screening. The assay allows concurrent confirmation and differential diagnosis of CAH and can be performed on the same DBS samples as in primary screening, enabling early diagnosis and treatment. (C) 2015 S. Karger AG, Basel
机译:背景/目的:新生儿筛查先天性肾上腺皮质增生(CAH)通常是使用17-羟孕酮离解增强的镧系元素荧光免疫测定法(DELFIA(R))进行的。由于高假阳性率,必须确认初步筛查结果;但是,需要获得单独的标本会妨碍早期识别,鉴别诊断和治疗。我们旨在开发一种单一液相色谱-串联质谱(LC-MS / MS)方法,该方法可使用与初筛时相同的干血斑(DBS)进行CAH的确认和鉴别诊断。方法:开发了一种LC-MS / MS方法,用于皮质醇,21-脱氧皮质醇,11-脱氧皮质醇,4-雄烯二酮和17-羟基孕酮的测定,验证,并将其应用于在交叉新生儿初筛筛查中呈阳性的总共163个DBS样品。边境合作。结果:只需简单的样品制备而无需衍生化,即可在DBS样品中实现出色的基线分辨率和所有分析物的可靠测定。在初步筛选中被测试为阳性的总共163个DBS样品中,在1个样品中证实了21-羟化酶缺陷型CAH。结论:目前的LC-MS / MS测定法已成功地用作跨境合作新生儿筛查的第二级检验。该测定法可同时确认和鉴别CAH,并可与初筛时在相同的DBS样品上进行,从而能够早期诊断和治疗。 (C)2015 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号